Critical Contrast: Benitec Biopharma (NASDAQ:BNTC) versus LENZ Therapeutics (NASDAQ:LENZ)

LENZ Therapeutics (NASDAQ:LENZ) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Volatility & Risk

LENZ Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Valuation and Earnings

This table compares LENZ Therapeutics and Benitec Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$20.99 million	7.74	-$82.13 million	($3.60)	-1.44
Benitec Biopharma	N/A	N/A	-$37.92 million	($1.14)	-11.21

Benitec Biopharma has lower revenue, but higher earnings than LENZ Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LENZ Therapeutics and Benitec Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Benitec Biopharma	N/A	-34.82%	-34.11%

Institutional & Insider Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for LENZ Therapeutics and Benitec Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	2	1	5	0	2.38
Benitec Biopharma	1	2	6	0	2.56

LENZ Therapeutics presently has a consensus target price of $29.80, indicating a potential upside of 475.29%. Benitec Biopharma has a consensus target price of $27.00, indicating a potential upside of 111.27%. Given LENZ Therapeutics’ higher probable upside, equities analysts plainly believe LENZ Therapeutics is more favorable than Benitec Biopharma.

Summary

Benitec Biopharma beats LENZ Therapeutics on 7 of the 13 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Benitec Biopharma

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.